NFE2L2 and cancer: However, the opposing regulatory genes of 108 by Nrf1 and Nrf2 were clustered into pathways in cancer, including the PI3K-AKT, p53, VEGF and JAK-STAT signaling, and ECM-receptor interacting EMT process, aside from antioxidant and inflammatory responses (Figure 14A).